Viral hepatitis and HIV coinfection

[Guest guest]

J Hepatol. 2007 Dec 4 [Epub ahead of print]

Viral hepatitis and HIV coinfection.

Sulkowski MS.

s Hopkins University School of Medicine, 600 North Wolfe Street, 1830

Building, Room 448, Baltimore, MD 21287, USA.

Persons at high risk for human immunodeficiency virus (HIV) infection are also

likely to be at risk for other infectious pathogens, including hepatitis B virus

(HBV) or hepatitis C virus (HCV). These are bloodborne pathogens transmitted

through similar routes; for example, via injection drug use (IDU), sexual

contact, or from mother to child during pregnancy or birth. In some settings,

the prevalence of coinfection with HBV and/or HCV is high. In the context of

effective antiretroviral therapy (ART), liver disease has emerged as a major

cause of morbidity and mortality in HIV-infected persons. Further, coinfection

with viral hepatitis may complicate the delivery of ART by increasing the risk

of drug-related hepatoxicity and impacting the selection of specific agents

(e.g., those dually active against HIV and HBV). Expert guidelines developed in

the United States and Europe recommend screening of all HIV-infected persons for

infection with HCV and HBV and appropriate management of those found to be

chronically infected. Treatment strategies for HBV infection include the use of

nucleos(t)ide analogues with or without anti-HIV activity and/or peginterferon

alfa (PegIFN) whereas HCV treatment is limited to the combination of PegIFN and

ribavirin (RBV). Current approaches to management of HIV-infected persons

coinfected with HBV or HCV are discussed in this review.

PMID: 18155314 [PubMed - as supplied by publisher]

_________________________________________________________________

The best games are on Xbox 360. Click here for a special offer on an Xbox 360

Console.

http://www.xbox.com/en-US/hardware/wheretobuy/

[Guest guest]

J Hepatol. 2007 Dec 4 [Epub ahead of print]

Viral hepatitis and HIV coinfection.

Sulkowski MS.

s Hopkins University School of Medicine, 600 North Wolfe Street, 1830

Building, Room 448, Baltimore, MD 21287, USA.

Persons at high risk for human immunodeficiency virus (HIV) infection are also

likely to be at risk for other infectious pathogens, including hepatitis B virus

(HBV) or hepatitis C virus (HCV). These are bloodborne pathogens transmitted

through similar routes; for example, via injection drug use (IDU), sexual

contact, or from mother to child during pregnancy or birth. In some settings,

the prevalence of coinfection with HBV and/or HCV is high. In the context of

effective antiretroviral therapy (ART), liver disease has emerged as a major

cause of morbidity and mortality in HIV-infected persons. Further, coinfection

with viral hepatitis may complicate the delivery of ART by increasing the risk

of drug-related hepatoxicity and impacting the selection of specific agents

(e.g., those dually active against HIV and HBV). Expert guidelines developed in

the United States and Europe recommend screening of all HIV-infected persons for

infection with HCV and HBV and appropriate management of those found to be

chronically infected. Treatment strategies for HBV infection include the use of

nucleos(t)ide analogues with or without anti-HIV activity and/or peginterferon

alfa (PegIFN) whereas HCV treatment is limited to the combination of PegIFN and

ribavirin (RBV). Current approaches to management of HIV-infected persons

coinfected with HBV or HCV are discussed in this review.

PMID: 18155314 [PubMed - as supplied by publisher]

_________________________________________________________________

The best games are on Xbox 360. Click here for a special offer on an Xbox 360

Console.

http://www.xbox.com/en-US/hardware/wheretobuy/